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MaTestosterone (T) is the principal male sex hormone. As men age, T levels typically fall. Symptoms of low T include
decreased libido, vasomotor instability, and decreased bone mineral density. Other symptoms may include depression,
fatigue, erectile dysfunction, and reduced muscle strength/mass. Epidemiology studies show that low levels of T are
associated with more atherosclerosis, coronary artery disease, and cardiovascular events. However, treating hypogo-
nadism in the aging male has resulted in discrepant results in regard to its effect on cardiovascular events. Emerging
studies suggest that T may have a future role in treating heart failure, angina, and myocardial ischemia. A large, pro-
spective, long-term study of T replacement, with a primary endpoint of a composite of adverse cardiovascular events
including myocardial infarction, stroke, and/or cardiovascular death, is needed. The Food and Drug Administration
recently put additional restrictions on T replacement therapy labeling and called for additional studies to determine its
cardiac safety. (J Am Coll Cardiol 2016;67:545–57) © 2016 by the American College of Cardiology Foundation.T estosterone (T) is the principal male sex hor-mone, secreted primarily by the testes and,to a lesser extent, by adrenal glands. This
hormone’s androgenic effects are responsible for the
maturation of male sexual organs, as well as for
secondary sexual characteristics (growth of beard,
axillary, and pubic hair, and deepening of voice). T
is needed for the development of normal sperm pro-
duction and contributes to sex drive. It also has
anabolic effects, including promotion of muscle
mass, strength, bone density, and maturation. T is
also produced in small quantities in the ovaries;
women have a much lower level of T than men. T
levels decrease with age, and this decrease has been
associated with an increase in atherosclerosis and
cardiovascular risk. One might conclude that replac-
ing T would reduce the risk; however, clinical studies
on this concept have shown discrepant results.
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and the elderly, the association between low T and
cardiovascular (CV) risk, and approaches to treating
hypogonadism. This review will also discuss contro-
versies regarding the administration of exogenous
T to patients with hypogonadism, the use of T in
heart failure, its effect on thromboembolism and
ischemia/reperfusion injury, and recent changes in
labeling for T replacement therapy (TRT).
THE HYPOTHALAMUS-PITUITARY-TESTES AXIS
The controller of the gonadal axis is gonadotropin-
releasing hormone (GnRH), which is released from
the hypothalamus (Figure 1). GnRH acts on the ante-
rior pituitary to stimulate release of luteinizing
hormone (LH) and follicle-stimulating hormone
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Leydig cells, and FSH stimulates spermatogenesis byivision of Cardiovascular Medicine, Department of
s Angeles, California; cDepartment of Urology, Uni-
logy, Johns Hopkins University School of Medicine,
sota; and the fSection of Vascular Medicine, Division
of Pennsylvania, School of Medicine, Philadelphia,
n is a consultant for Abbvie, Boston Scientific, and
consultant for Prime Therapeutics. Dr. Mohler is a
FIGURE 1 GnRH Acts on the Anterior Pituitary to Stimulate
Release of LH and FSH
In men’s testes, LH stimulates testosterone synthesis by Leydig
cells, and FSH stimulates spermatogenesis by Sertoli cells.
Testosterone then feeds back to the hypothalamus and pituitary,
completing a negative feedback loop. FSH ¼ follicle-stimulating
hormone; GnRH ¼ gonadotropin-releasing hormone;
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546Sertoli cells. Only a small fraction of the total
circulating T is in a free form, with the vast
majority bound to sex hormone-binding
globulin (SHBG) or albumin. Biologically
active, free T binds to the androgen receptor
present in the cytosol of most tissues (1). The
T-androgen receptor complex then migrates
to the nucleus, where it stimulates tran-
scription of numerous genes. Interestingly,
T serves as a prohormone for estradiol, via
the action of the aromatase enzyme (pre-
sent in many cardiovascular cell types), and
dihydrotestosterone (DHT), via 5a-reductase
activity. DHT is a more potent androgen
than T, on the basis of its greater affinity
for the androgen receptor and long resi-
dence time. However, circulating levels of
DHT are generally one-tenth or less those of
T. T, DHT, and estradiol then complete a
negative feedback loop to the hypothalamus
and pituitary. Several clinical conditions,
including obesity, type 2 diabetes mellitus,
hypothyroidism, polycystic ovarian syn-
drome, and nephrotic syndrome decrease
SHBG levels (2), which can result in relatively
more free T for any given total T. Older age,
hyperthyroidism, and cirrhosis increaseLH ¼ luteinizing hormone; T ¼ testosterone.SHBG levels and can result in a free T concentration
in the hypogonadal range, despite normal total
T levels.
DEFINITION OF HYPOGONADISM
Male hypogonadism is the term used to describe a
deficiency of T secretion from the Leydig cells of the
testes (Figure 1). Depending on the pathophysiology,
it may or may not be associated with infertility due to
reduced spermatogenesis in the seminiferous tu-
bules. Similarly, infertility may or may not be asso-
ciated with hypogonadism. As an example, there are
often microdeletions of the Y chromosome that are
associated with male infertility, but with normal
T synthesis.
Hypogonadism is classified as primary (testicular
failure) or secondary, centrally mediated (hypotha-
lamic or pituitary in etiology). Causes of primary
failure include radiation therapy, trauma, infection
(mumps), and ischemia (torsion). Common medica-
tions, including opioids, suppress release of GnRH
from the hypothalamus, and glucocorticoids, which
bind to the gonadotropic cell receptors, result in
central suppression of the hypothalamus and pitui-
tary. Milder forms of hypogonadism exist and are
associated with aging and chronic disease.LABORATORY DIAGNOSIS. The laboratory diagnosis
of hypogonadism requires documentation of low
serum T levels on at least 2 morning samples drawn
before 10 AM. Free T is considered the better test
because total T can be elevated in situations of
elevated SHBG (aging), or the total can be low when
SHBG levels are reduced (diabetes, obesity). An
analysis for FSH and LH should be done to distinguish
between primary versus centrally mediated hypo-
gonadism. If a pituitary tumor is of concern, then a
prolactin level should be obtained. Although most
agree that a total T of <300 ng/dl is considered low, it
is best to use the normal ranges of the specific labo-
ratory making the measurement.
SIGNS AND SYMPTOMS OF HYPOGONADISM. Signs
and symptoms of hypogonadism (Central Illustration)
are related to the patient’s age. For example, delayed
puberty is clearly a problem of congenital or
childhood-associated hypogonadism. However, the
changes in a post-pubertal male can be much more
subtle. The Endocrine Society diagnostic guidelines
for hypogonadism require both documentation of
serum gonadal tests (at least 2 morning samples) and
CENTRAL ILLUSTRATION Testosterone Has
Multiple Effects on the Body
ROLE OF TESTOSTERONE IN THE BODY
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 Kloner, R.A. et al. J Am Coll Cardiol. 2016; 67(5):545–57.
Testosterone affects the brain with stimulation of libido and
aggression; muscle strength and mass; bone growth and den-
sity; sex organ growth, along with spermatogenesis and erectile
function; kidney production of erythropoietin; and skin effects,
including hair growth. T ¼ testosterone.
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547the presence of symptoms (3). Specific signs and
symptoms of male hypogonadism include vasomotor
instability (hot flashes), decreased libido (4), and
decreased bone mineral density (BMD) (5). There are
clear data that T treatment will relieve hot flashes,
improve libido, and increase bone mass (6). Similarly,
there are consistent data from both the literature (7)
and from studies of frail older men (8) that T ther-
apy will increase lean body mass. In the recently
published TOM (Testosterone in Older Men With
Mobility Limitations) study, this increase in muscle
mass translated to improved strength (8).
The data on erectile function generally show an
improvement with T therapy, but the benefit is morepronounced in men with lower serum levels of T at
baseline and in younger, healthier men, with little
vascular disease.
Numerous studies have shown an age-related
decline in both total and free T, even in the pres-
ence of an age-related increase in SHBG (9). The
defect is thought to occur mainly at the level of the
hypothalamus and pituitary gland, and is character-
ized as a blunted response to GnRH stimulation.
Approximately 25% of men >65 years of age will have
low total T levels, and at least 50% will have low
levels when using free T as the diagnostic criterion.
Similarly, there are numerous chronic illnesses
associated with reductions in serum T that can be
attributed to inflammation with elevated cytokines.
The frequency of male hypogonadism varies greatly
on the basis of the population studied. It is no
surprise that sicker men will have age-related de-
clines. In population-based studies, the prevalence of
hypogonadism is 54% in a hospitalized, ill population
(10,11) and 50% among type 2 diabetes mellitus
patients (12). As with age-related decline, it is unclear
whether chronic illness-related decline should be
treated with T therapy.
The less specific findings of reduced T levels
include depression, fatigue, erectile dysfunction
(ED), and reduced muscle mass. These nonspecific
symptoms can be difficult to define in clinical trials.
There is some improvement in the overall sense
of well-being with T therapy (13), but the data are
relatively few when it comes to randomized, placebo-
controlled studies. One reason for this is the
variability in age, symptoms, and serum T levels in
the enrolled populations. It must be emphasized that
the Food and Drug Administration (FDA) has never
required that any new T product prove efficacy.
The FDA only requires adequate pharmacokinetics.
LOW T LEVELS AND CARDIOVASCULAR RISK
As stated, serum T level declines gradually with age
in most men (14). Epidemiological and observational
studies have shown that low T is associated with
increased CV disease risk (15–17). A meta-analysis of
70 studies indicated that patients with CV disease
demonstrated significantly lower T and higher 17-b
estradiol levels, which remained significant markers
after adjusting for age and body mass index (16). In
longitudinal studies, the baseline T level was lower in
those with cardiovascular mortality.
Recent studies have described a relationship
between low levels of endogenous T and atheroscle-
rosis, coronary artery disease, or CV events. Men in
the highest tertiles of T and bioavailable T had lower
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548relative risk of abdominal aortic atherosclerosis than
men in the lowest tertile (18). Rosano et al. (19) found
that patients with coronary artery disease had lower
T levels than controls. Ohlsson et al. (20) observed that
both serum T levels and SHBG levels were inversely
related to the incidence of adversemajor CV events. Hu
et al. (21) described lower levels of T in men with cor-
onary artery disease symptoms than in controls. Some
studies have shown a negative correlation between the
degree of angiographic coronary disease and T levels
(19,21–23). In a recent paper, Alkamel et al. (23)
described an association between low serum T levels
and premature coronary artery disease inmen 45 years
of age and younger. Farias et al. (24) found a negative
correlation between carotid intimal thickness and total
T concentration in middle-aged men with type 2 dia-
betes. Patients who had low T levels were also more
likely to demonstrate atherosclerotic plaques, endo-
thelial dysfunction, and higher levels of high-
sensitivity C-reactive protein. Lee et al. (25) observed
a significant negative correlation between the level of
total T and the Framingham Risk Score. Therefore, a
host of observational studies suggest an association
between low T levels and the presence of atheroscle-
rosis, coronary artery disease, and coronary events. As
recently stated by Shores and Matsumoto (26), “it is
unclear if this is a causal association or due to low T
being a biomarker of poor health.”
THE USE OF TRT FOR YOUNG OR
CONGENITAL HYPOGONADAL PATIENTS
Boys and men with a clear diagnosis of hypogonadism
require life-long TRT. Examples include primary
testicular failure from congenital causes, such as
Klinefelter’s syndrome (XXY), acquired testicular
failure from mumps orchitis, or secondary testicular
failure caused by alkylating agents.
For congenital causes, boys should start therapy
about the time of normal puberty (i.e., <14 years of
age) and continue for life. The type and route of
administration for T is primarily of personal prefer-
ence. Each differs by its pharmacokinetic profile or
frequency of administration (27).
Caution should be used in the administration of
T therapy to men who may be interested in fertility.
One of the clear side effects of exogenous T is sup-
pression of the endogenous gonadal axis, resulting in
suppressed spermatogenesis.
THE USE OF TRT IN MATURE AND
OLDER MEN WITH HYPOGONADISM
Age-related hypogonadism is common (28) and
becoming more recognized, likely due, in part, to direct-to-consumer advertising. Various society guidelines
emphasize the need to not only measure serum sex
hormone levels (2morning samples, a few days apart),
but also to correlate them to symptoms and signs.
Unfortunately, many of the symptoms are nonspe-
cific, thus making it difficult to conclude whether the
presenting clinical scenario is due to aging or
hypogonadism.
The goal of TRT is to restore T levels to normal
physiological ranges and to reverse the physiological
effects of hypogonadism. Many placebo-controlled
and noncontrolled trials have been carried out to
investigate the effects of TRT in hypogonadal men
and establish outcomes for the signs and symptoms
that men experience from chronically low T (29). The
most extreme example of acute hypogonadism is in
men given androgen deprivation therapy (ADT) for
prostate cancer (30,31). ADT has been shown to have
severe adverse effects on metabolic markers, bone
density, fatigue, sexual function, and even cognition.
Reversing the effects with TRT and returning men to
eugonadal levels of T has been clearly shown to
reverse the effects of castrate levels of T achieved
with ADT (32). In men with clinical hypogonadism
without ADT, the studies of TRT have significant
weaknesses, including a low number of subjects,
variable selection criteria and definition of hypo-
gonadism, dose of T, duration of administration, and
outcomes measured (29).
TRT has been shown to improve symptoms of
sexual dysfunction in men with significantly
decreased T levels (33,34). Complaints of changes in
sexual function, including ED, ejaculatory dysfunc-
tion, and reduced libido are among the most common
presenting symptoms for hypogonadal men (34). The
field of ED has reliable, validated instruments to
assess symptoms of ED and its improvement
with therapy, and several studies have demonstrated
that T improves sexual dysfunction (35–38). Unfor-
tunately, sexual dysfunction can also be caused by
numerous other physiological abnormalities that
result in either decreased vascular supply to the
genitals or decreased libido (39). In addition, several
studies have demonstrated the combination of TRT
and a phosphodiesterase type 5 inhibitor to be bene-
ficial for hypogonadal men with ED and have sug-
gested an additive effect of these treatments (40,41).
Mood, depression, and cognition changes have
been widely reported in association with hypo-
gonadism (42,43). Studies have reported measurable
depressive symptoms in men with significantly low
T levels (43). The data on these changes and the
benefits of TRT are less clear than with sexual
dysfunction (44–48).
J A C C V O L . 6 7 , N O . 5 , 2 0 1 6 Kloner et al.
F E B R U A R Y 9 , 2 0 1 6 : 5 4 5 – 5 7 Testosterone and Cardiovascular Disease
549Fatigue is a common complaint of hypogonadal
men seeking treatment (49,50). Fatigue and vigor
improved in a placebo-controlled trial of TRT
using a nonvalidated outcome instrument to assess
fatigue (50).
TRT has been extensively studied for changes in
muscle mass and body composition. The majority of
these studies of body composition in hypogonadal
men showed improvements by TRT in lean body mass
with decreased fat mass (51–54).
In a recent study (55), those men treated with
TRT and resistance training had a decrease in fat
mass, and increases in lean mass and upper body
strength compared with men taking placebo. In
the TOM study of frail elderly men with mobility
limitations, stair-climbing power, leg-press strength,
and chest-press strength were significantly
improved in men receiving TRT versus placebo (56).
Spitzer et al. (57) reviewed TRT benefits on physical
function, mobility, and frailty. Compared with men
with normal T levels, hypogonadal men had poorer
physical performance and mobility, and increased
frailty.
In randomized, double-blind, placebo-controlled
trials, TRT significantly increased BMD in hypo-
gonadal men (58). Aversa et al. (59) evaluated effects
of 36 months of TRT in a group of elderly men with
mild osteopenia, metabolic syndrome, and T
levels <320 ng/dl. BMD improved by 5% per year in
the lumbar and femoral bone measurements. Because
bone changes and osteopenia are often of long dura-
tion, TRT only results in a benefit for BMD when
followed for more than 1 year. Although loss of
height, fragility, fracture, and/or baseline abnormal
dual-energy X-ray absorptiometry scan showing
osteopenia are common indications for treatment
(60,61), there are no data suggesting that TRT rem-
edies bone fractures in fragile men (62). Thus, the use
of bisphosphonates or other specific treatments has
been advocated for true osteoporosis (63).
Hypogonadism is common in men with metabolic
syndrome and type 2 diabetes mellitus, and is also
associated with poor glycemic control, insulin resis-
tance, visceral adiposity, and dyslipidemia (64,65).
Diabetes mellitus is associated with hypogonadism in
as many as 50% of patients with type 2 diabetes (50).
In a recent review of 4 randomized clinical trials of
TRT in hypogonadal men with type 2 diabetes melli-
tus, Corona et al. (66) reported that TRT contributed
to reductions in fat mass, glycosylated hemoglobin
(HbA1c), fasting plasma glucose, and triglycerides, but
produced no significant improvement in total and
high-density lipoprotein, cholesterol, blood pressure,
or body mass index. In a more recent meta-analysis of5 studies of hypogonadal men with diabetes, Cai et al.
(67) reported improvement in HbA1c, fasting plasma
glucose levels, fasting serum insulin, and triglyceride
levels.
In summary, regardless of age, men with low
serum T below the normal range and with convincing
signs and symptoms of hypogonadism should be
offered therapy. In all situations, there should be
careful and thorough monitoring of complete blood
count and prostate-specific antigen (PSA) for poten-
tial side effects. In addition, serum-free and/or total
T levels should be monitored to ensure appropriate
goal levels are met. Health care providers should
discontinue T therapy, not only for adverse events,
but also for lack of efficacy.
THE CONTROVERSY REGARDING THE EFFECT
OF TRT ON THE CARDIOVASCULAR SYSTEM
Whereas most epidemiological studies have sug-
gested that low T is associated with increased
atherosclerotic disease (68), there is a raging contro-
versy about the effects of TRT on CV events and
mortality. Meta-analyses published between 2005
and 2010 (69–71) show that TRT, in general, had
neutral effects on the occurrence of major, adverse
CV events; T did increase hematocrit and hemoglo-
bin, and had various small effects on lipid levels.
A paper by Basaria et al. (56), published in 2010
in the New England Journal of Medicine, entitled
“Adverse Events Associated With Testosterone
Administration,” was the first of 3 original papers to
warn physicians that there could be a potential issue
regarding the administration of T and CV safety. The
TOM trial was a placebo-controlled, randomized
study designed to assess the effects of administering
exogenous T gel or placebo on physical functioning
and lower extremity strength in men 65 years and
older who had baseline limited mobility and low total
serum T levels. Adverse events were monitored by a
data and safety monitoring board that stopped the
study early because of a higher rate of CV events in
the treated group. The men who received T did
demonstrate greater increases in leg-press strength
and other measures of muscle strength. However, 23
men in the T group versus 5 in the placebo group
demonstrated CV-related adverse events of variable
clinical importance. Some were major events, such as
myocardial infarction (MI) (2 in the treated group),
but others were softer endpoints and may not have
been truly cardiac or may have been unrelated to the
medicine (syncope, edema, ectopy on electrocardio-
gram [ECG], left ventricular strain pattern on an ECG,
tachycardia with fatigue, carotid bruit, elevated blood
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pointed out, including that the participants had a
high prevalence of chronic conditions, including pre-
existing CV disease and risk factors for CV disease,
and represented one population of older, immobile
men, who received, in general, very high doses of T. It
is not possible to extrapolate these findings to other
formulations or doses of T, or to men with hypo-
gonadism who do not have underlying CV disease,
risk factors for CV disease, or mobility issues.
Vigen et al. (72) studied the relationship between
T therapy and all-cause mortality, MI, and stroke in a
population of male veterans. The study was a retro-
spective cohort analysis of men with low T levels
(<300 ng/dl) who underwent coronary angiograms in
the Veterans Affairs system. The primary outcome
was the composite of all-cause mortality, MI, and
stroke. At 3 years, Kaplan-Meier estimated cumula-
tive percentages with the primary outcome were
19.9% in the no-T group and 25.7% in the T group.
T was associated with an increase in events.
This paper has stirred much discussion. Some in-
vestigators pointed out that the raw data, before
various statistical adjustments, actually showed an
outcome that favored T (73–77). In their paper, the
investigators state: “Of the 7486 patients not
receiving T therapy, 681 died, 420 had MIs, and 486
had strokes” [italics added] (72). Therefore, 681 þ
420 þ 486 ¼ 1,587/7,486 ¼ 21% of patients not
receiving T had an event. The investigators also state:
“Of the 1223 patients receiving T therapy, 67 died, 23
had MIs, and 33 had strokes” (72). Therefore, 67 þ
23 þ 33 ¼ 123/1,223 ¼ 10% of patients receiving T had
an event. Thus, if one looks at the raw numbers,
T was associated with an event rate that was reduced
by more than one-half, and it was not until statistical
manipulations were performed that the opposite
conclusion was reached. Other criticisms of this paper
included the concern that men with MI or stroke who
were given T after these events were excluded from
analysis. However, had they been included, the rate
of events in the no-treatment group would have been
substantially increased. Starting on T did not ensure
that it would be continued: 17.6% of patients in the
T group had only 1 prescription filled, and only 60% of
patients had follow-up T levels determined after
therapy had started. In those patients that did have
post-treatment levels determined, the average treat-
ment level was only 332 ng/dl, which is lower than the
usual therapeutic target level. Using patches in a large
number of patients (63% of those on T) is problem-
atic, as many patients suffer local reactions to the
patches. The investigators have printed some cor-
rections to the study, yet some investigators havecalled for retraction of this paper (78). The debate
continues.
A third study that has contributed to the contro-
versy regarding the safety of T was a paper published
in 2014 by Finkle et al. (79). This was a cohort study
that described the risk of developing a nonfatal
MI after an initial prescription for TRT. The data were
obtained from a large health care database and
included 55,953 patients who received T. The in-
vestigators compared the rate of nonfatal MI in the 90
days after the initial prescription for T to the rate in
the year before the prescription. The investigators
found that for all T prescription subjects, the rate
ratio (post/pre) was 1.36 (95% confidence interval
[CI]: 1.03 to 1.81). The rate/ratio was even higher in
men 65 years of age and older, at 2.19 (95% CI: 1.27 to
3.77); for men 75 years of age and older, it was 3.43
(95% CI: 1.54 to 7.56). For men younger than 65 years
of age, the increased risk of developing a nonfatal
MI was only observed in men with previous histories
of heart disease. Whereas one of the strengths of this
study was the large number of patients who were
analyzed, its limitations included that the diagnostic
indications for using T were not reported, and pre-
and post-treatment drug levels of T were not avail-
able (78–80). In addition, T exposure was defined as a
patient who had received a prescription for T. It is not
known whether the patient, once receiving a pre-
scription, actually had it filled, used it, or obtained
and used refills. Data on nonfatal MI were captured,
but data on other major adverse CV disorders (fatal
MI, CV mortality, stroke) were not captured in this
analysis. Three months is a relatively short time, and
follow-up may not have been adequate.
A very recent study compared CV events in men
receiving various forms of T therapy. Injection ther-
apy was associated with higher event rates than
topical gel or topical patches. However, this study did
not have a control group for comparison, making
interpretation incomplete (81).
Despite these recent studies showing an associa-
tion of adverse CV outcomes to exogenous T use,
there are an equal number of studies showing just the
opposite. Shores et al. (82) reported an observational
study of 1,031 male veterans, 40 years of age and
older, who had low total T levels. Of the 1,031 men,
39% received T therapy as part of their routine med-
ical care. Over an average follow-up time of 41
months, the death rate was 20.7% in men who did not
receive T, and there were 5.7 deaths per 100 person-
years; in men receiving T, the death rate was signifi-
cantly lower, at 10.3%, and there were 3.4 deaths per
100 person-years. Even after the investigators
adjusted for a number of confounding variables, the
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551risk of death was lower with T. The investigators
pointed out many of the limitations of the study,
including that it was observational, and bias may
have been introduced. For example, physicians may
have selected healthier men to receive T treatment.
Other limitations were that study entry was based
upon a single level, rather than at least 2 levels, as
suggested by clinical guidelines; the investigators did
not uniformly obtain T levels in the morning; levels of
free T were not obtained; and symptoms of low T
were not determined. The investigators do point out
that in a prior study of the same patient group, the
most common reasons for obtaining T levels were
sexual dysfunction, osteoporosis, and urologic or
endocrine disorders (83).
Baillargeon et al. (84) reported the risk of MI in a
cohort of men 65 years of age and older receiving T,
using a national sample from the Medicare benefi-
ciary database. They identified 6,355 men who had
received at least 1 intramuscular T treatment between
January 1, 1997, and December 31, 2005, and then
matched this cohort to 19,065 men who had not used
T. The investigators reported that there was no
increased risk of MI associated with T use. Of note, for
men in the highest quartile of risk for MI, T therapy
was associated with a lower incidence of MI. The in-
vestigators pointed out some of the limitations of
their study. Their information on risk factors and
outcomes were derived from diagnostic codes and
charges for outpatient and hospital services; other
formulations of T therapy were not assessed; and
they did not determine use of other agents that may
have reduced MI risk. Furthermore, their analysis did
not capture medicines received outside the health
plan. Baseline T levels were not available in the
Medicare claims database. Because this was an
observational study, selection bias might have been
present.
There have been a few clinical trials that have
focused on the use of T replacement therapy in hypo-
gonadal men with diabetes or metabolic syndrome
(85–87). These studies suggested that TRT reduced
insulin resistance (85,87), improved survival, reduced
major adverse CV events (85), and reduced ischemic
burden (86) on ambulatory ECG monitoring (87).
Results of recent meta-analyses on the effects of
TRT on CV risk have been contradictory, with one
suggesting that TRT increases adverse CV events in
studies not funded by pharmaceutical companies
(88), and another showing that T was not associated
with major adverse CV events and was actually pro-
tective in men with metabolic syndrome (89).
At the present time, the issue of the CV safety of T
remains controversial (77,90–92). Some of the majorreasons might include differences among the trials
in inclusion and exclusion criteria; baseline T levels
and degree of clinical hypogonadism; age; weight;
underlying CV risk factors; patient mobility; duration
of the study; variability in the definition of major
adverse CV events; variability in the type of T prep-
aration used (81); and lack of follow-up on T levels
after starting TRT. However, 1 recent retrospective
study examined the effect of TRT on normalization
of total T levels and the effect of therapy on major CV
outcomes. Sharma et al. (93) studied male veterans
with low total T levels and described the association
of TRT with all-cause mortality, MI, and stroke in
3 groups: those not receiving TRT; those receiving
TRT and achieving a normal total T level; and
those receiving T and failing to achieve a normal T
level. Patients who received TRT and achieved
normal levels had significantly lower all-cause mor-
tality, lower risk of MI, and lower risk of stroke
compared with patients who either were not on TRT
or those on TRT who did not achieve a normal total
T level.
Other reasons for discrepancies in published re-
ports might relate to the type of T that is measured.
Some investigators think that free T or bioavailable
T levels should be measured, as well as total T. The
types of statistical analyses in these studies were
variable, and as pointed out, 1 study showed raw
numbers that favored T therapy, whereas extensive
statistical recalculation showed a detrimental effect
of this therapy (72,73). The lack of prospective,
double-blinded, placebo-controlled, randomized tri-
als, in which major adverse CV events are a primary
endpoint makes it difficult to determine the effect
of T on the CV system. The National Institutes of
Health-sponsored Testosterone Trials (T Trials),
prospective, randomized studies of testosterone gel,
were recently completed and included a trial eval-
uating the CV effects of T (94). The results will
provide further assessment of CV risk after treat-
ment with T.
PROPOSED PROSPECTIVE STUDY
A proposed study to definitively answer the question
of whether TRT has adverse effects on CV safety is
needed. It should be a large, prospective, random-
ized, placebo-controlled, double-blinded, long-term
study (at least 1 year and preferably longer).
Entrance criteria should require the men to have
symptomatic hypogonadism, verified by low T (total,
free, bioavailable) levels obtained on at least 2 sepa-
rate morning blood draws. At least 2 T-type prepara-
tions should be studied (intramuscular injections and
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dates). Follow-up T levels should be monitored
throughout the study. Major adverse CV/cerebrovas-
cular events (MI, stroke, CV death) should be the
primary endpoint and should be carefully defined.
Secondary endpoints should include the individual
components of the primary endpoints, hospitali-
zation for acute coronary syndrome and/or heart
failure, patient’s vital signs (heart rate and blood
pressure), ECG, as well as prostate abnormalities.
Other secondary endpoints should include efficacy
measures for T, such as questionnaires related to
sexual health (libido and erectile function), tests of
muscle strength, muscle mass, adiposity, effects of
T on lipid and glucose levels, as well as insulin
resistance, PSA, and other biomarkers. This proposed
study should include thousands of patients studied
over several years and, as it would be very expensive
to carry out, include a consortium of pharmaceutical
companies or government support, or perhaps a
hybrid of support mechanisms.
POTENTIAL FUTURE CARDIOVASCULAR
USES OF T
Besides safety issues of T, there has also been interest
in its use as a potential therapy for certain CV disor-
ders. These include using T for heart failure, angina,
and ischemia/reperfusion injury.
T THERAPY IN HEART FAILURE WITH
REDUCED EJECTION FRACTION
T deficiency (total and estimated free T) has been
demonstrated in 26% to 37% of male patients with
chronic heart failure (HF) with reduced ejection
fraction (95–97). Reduced T levels are associated with
increased systemic vascular resistance, lower heart
rate variability, and depleted baroreflex sensitivity
(98,99). In addition to the chronic anabolic state seen
in HF, the reasons for reduced T levels are likely
multifactorial, with hepatic congestion leading to an
increase in SHBG levels, with a subsequent decrease
in free T levels (100,101). Low T is frequently associ-
ated with impaired exercise tolerance and can exac-
erbate symptoms in patients with HF with reduced
ejection fraction (101). The physiological pathways
have not been fully delineated, but suggest a
contributing role for reduced T in the symptomatic
decline seen in HF. In men with HF, the rise in
T levels seen with replacement therapy is a significant
predictor for an increase in peak oxygen consumption
(VO2) on exercise testing (102). T, administered
intravenously, will acutely increase cardiac output
and reduce peripheral vascular resistance (103).During chronic replacement, T therapy can reduce
circulating levels of inflammatory mediators,
including tumor necrosis factor alpha (TNF-alpha)
and interleukin-1beta, thus potentially leading to a
reduction of left ventricular muscle fibrosis (104).
EFFECT OF T SUPPLEMENTATION
IN PATIENTS WITH SYSTOLIC HF
Toma et al. (105) conducted a meta-analysis of ran-
domized controlled trials evaluating the effect of TRT
on exercise capacity in HF patients. The 4 studies
(N ¼ 198; men, 84%; mean age 67 years) tested either
transdermal or intramuscular T, given between
12 weeks to 12 months, and included an endpoint of a
6-min walk test (6MWT), incremental shuttle walk
test, or peak VO2 by cardiopulmonary exercise test.
They reported that 6MWT increased by 54.0 m, in-
cremental shuttle walk test increased by 46.7 m, and
peak VO2 increased by 2.7 ml/kg/min in the TRT pa-
tients versus placebo. The increase in peak VO2 and
distance walked in the TRT group correlated with the
increase in free or bioavailable T (105). This degree of
improvement in the 6MWT is similar to that seen with
other therapies in patients with HF. Interestingly,
neither left ventricular ejection fraction (106–109) nor
B-type natriuretic peptide (104,106) changed signifi-
cantly in any of the studies in which they were re-
ported. New York Heart Association functional class
improved by $1 grade in 9.8% of patients in the pla-
cebo groups versus 35% of patients in the TRT group.
There were no significant differences in major
adverse cardiac events between the TRT and placebo
groups (105). The results are likely relevant to
women, on the basis of the suspected mechanisms of
action and the corroborative results seen in 1 study
that included only female patients with HF (107).
T IN MYOCARDIAL ISCHEMIA/REPERFUSION
Nicolli et al. (110) showed that patients who presented
with ST-segment elevation MIs with angiographic or
electrocardiographic evidence of microvascular
obstruction were more likely to have low T levels than
those without microvascular obstruction. This corre-
lates with findings suggesting that T can induce
relaxation of the coronary arteries (111). Malkin et al.
(112) studied the effect of TRT in 10 men with
ischemic heart disease and low T levels. Following
1 month of therapy, TRT had improved time to a 1-mm
ST-segment depression on a Bruce protocol exercise
treadmill test (increased by 74 s), improved mood
assessed by questionnaire, reduced total cholesterol,
and reduced serum TNF-alpha (one marker of
inflammation). In a follow-up study, Mathur et al.
TABLE 1 Testosterone’s Role in Therapy of True Symptomatic
Hypogonadism in Young and Older Men
Organ Young Men Older Men Ref. #
Libido ++ ++ 33–38
Erectile function ++ ++ 33–38
Cardiovascular + + 69–71
Mood + + 42,43
Cognition + + 47,48
Energy + + 49,50
Bone mineral density ++ ++ 58–63
Fat mass ++ ++ 54
Hematopoiesis ++ ++ 69,71
Muscle mass ++ ++ 53–55
Muscle strength ++ ++ 54–56
Insulin sensitivity + + 67
Sperm count     121
þþ ¼ strong evidence of positive effect; þ ¼ weak evidence of positive effect;
  ¼ strong evidence of negative effect;  ¼ weak evidence of negative effect.
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553(113) tested the effect on ischemia of TRT during
12 months of treatment. Long-term treatment with
T again increased time to develop ischemia on a
treadmill (129 s in T patients vs. 12 s in placebo pa-
tients, p ¼ 0.02). Some, but not all, experimental
animal studies have suggested that T administration
might reduce myocardial infarct size. Herring et al.
(114) and other scientists have recently reviewed
these studies (115). In the Kloner laboratory, admin-
istration of T starting 1 week before experimental MI
in the rabbit had a neutral effect on MI size, but did
shorten the QT interval corrected for heart rate (116).
Larger studies are needed to determine whether T has
future potential as an anti-ischemic, antianginal
therapy.TABLE 2 Cardiovascular Effects of TRT
Cell/Tissue Physiological Effect
Endothelial function Enhanced vasodilatation
Hemodynamics Decreased SVR
Decreased LVEDP
CV inflammation and
atherosclerosis
No consistent data on CIMT, CRP, IL-1b, IL-6, IL
TNF-a
Conduction tissue Decreased action potential duration and early a
depolarizations
Lipid levels No consistent effects demonstrated
Myocardial protection Activation of STAT3
Atheroma No consistent effect on VCAM1
Hemostasis Increased TXA2 platelet aggregation
CIMT ¼ carotid artery intima-media thickness; CRP ¼ high-sensitivity C-reactive prot
ventricular ejection fraction; QTc ¼ QT interval corrected for heart rate; STAT3 ¼ cardiop
cell adhesion molecule-1; SVR ¼ systemic vascular resistance; TNF ¼ tumor necrosis f
expression; VCAM1 ¼ vascular cell adhesion molecule 1.T AND DEEP VENOUS THROMBOSIS
The FDA label for T formulations includes venous
thrombosis as a potential consequence of poly-
cythemia that sometimes occurs in response to TRT.
The FDA recently instructed manufacturers to
broaden the T label warning of venous thrombosis to
include risk, without necessarily having poly-
cythemia. The broadened warning regarding venous
thrombosis is on the basis of reports of venous
thrombosis unrelated to polycythemia and from
observational studies. One such study was a series of
9 patients reported to have a deep vein thrombosis or
pulmonary embolism temporally related to T use
(117). However, a case-controlled study of 30,572
men, 40 years of age or older, showed that T therapy
in the 15 days before the event or index date was not
associated with increased risk for venous thrombo-
embolism and was not associated with administration
route. When the exposure window was expanded to
30 or 60 days before the event, the study results did
not significantly change (118). There are no prospec-
tive studies showing an association between T sup-
plementation and venous thrombosis. Thus, the
effect of T on the risk of venous thrombosis, beyond
the impact of polycythemia, is unclear.
FDA-MANDATED CHANGE IN
LABELING FOR TRT
On September 17, 2014, the U.S. FDA convened an
advisory committee to review the use of TRT and its
CV risks. The committee was asked to give an opinion
on the current indications for TRT and whether
manufacturers of T products should conduct studies
to assess CV risks with the use of TRT. The committeeClinical Effect Ref. #
Increased peripheral and coronary blood flow 111,112
Increased cardiac output 103,111,115
-10, None 104
fter- Shortens QTc interval, resulting in improved
antiarrhythmic substrate
116
None 69–71
Decreased reperfusion injury 115
No consistent effect on atherogenesis 113
Thrombosis 117
ein; IL ¼ interleukin; LVEDP ¼ left ventricular end-diastolic pressure; LVEF ¼ left
rotective signal transducer and activator of transcription; sVCAM-1 ¼ soluble vascular
actor; TRT ¼ testosterone replacement therapy; TXA2 ¼ thromboxane A2 receptor
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554panel concluded that there was not enough evidence
that TRT was a significant CV risk for any given group
of patients treated with TRT. The committee com-
mented, however, that TRT safety in high CV-risk
groups, such as older, diabetic, and obese men,
needed further studies (119).
In March 2015, the FDA clarified recommendations
for the use of TRT (120). They stated that TRT is
approved only for men with documented low
T caused by specific medical conditions. They also
wrote that the benefits and safety of TRT are not
clear for the aging male with low T, even if
symptomatic.
In June 2015, the FDA further required manufac-
turers of TRT products to change their labeling to
include additional warnings (119). These caveats
included: TRT is indicated for replacement therapy
only in males with conditions associated with a
deficiency in endogenous T, specifically primary
hypogonadism (congenital or acquired) or hypo-
gonadotropic hypogonadism (congenital or acquired).
Before initiating TRT, providers must confirm the
diagnosis of hypogonadism by measuring serum T in
the morning on 2 separate days and confirm that
these levels are below the normal range. Providers
should make patients aware of the possible increased
CV risk when initiating TRT (119). These recommen-
dations on the product package inserts havestimulated insurance carriers to require similar mea-
surements and documentation of cardiac health
before paying for TRT.
CONCLUSIONS
Testosterone has a role in therapy of true symptom-
atic hypogonadism in both young and older men
(Table 1). There appear to be no major concerns for
using T in young, healthy men with specific in-
dications for TRT. Testosterone has specific effects on
the CV system (Table 2). The use of T in older men and
those with known coronary artery disease is contro-
versial. Asymptomatic, middle-aged and older men
without a history of heart disease should be coun-
seled about the uncertain CV risk. Randomized,
controlled trials are needed. Finally, in our opinion,
patients with recent MI, revascularization, poorly
controlled HF, or stroke within the last 6 months are
not good candidates for the initiation or maintenance
of TRT, given the uncertainty of CV risk.
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